Dr. Peter Odonnell
Internal Medicine (Internal Medicine Physician)
5841 S Maryland Ave, Mc 2115
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 98
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Chicago, Pritzker School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Internal Medicine Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Uchicago Medicine Northwest Indiana Crown Point, IN
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 98
- Services billed
- 210
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 87 | 42 |
| Established patient office or other outpatient visit, 40-54 minutes | 58 | 34 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Chicago, IL | 17 |
| Erleada (apalutamide) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 12 payments worth $18,281 in total to this clinician.
| Astellas Pharma US Inc | $7,236 |
|---|---|
| Astellas Pharma Global Development | $3,713 |
| Merck Sharp & Dohme LLC | $3,588 |
| Pfizer Inc. | $1,875 |
| Janssen Research & Development, LLC | $1,869 |
| Consulting Fee | $17,544 |
|---|---|
| Travel and Lodging | $598 |
| Food and Beverage | $138 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 3, 2025 | Consulting Fee Padcev · Oncology | $4,400 |
| Astellas Pharma Global Development Feb 19, 2025 | Consulting Fee Padcev · Oncology | $3,713 |
| Astellas Pharma US Inc Oct 10, 2025 | Consulting Fee Padcev · Oncology | $2,100 |
| Merck Sharp & Dohme LLC Dec 1, 2025 | Consulting Fee | $1,920 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee PADCEV · ONCOLOGY | $1,875 |
| Janssen Research & Development, LLC Aug 12, 2025 | Consulting Fee | $1,438 |
| Merck Sharp & Dohme LLC Jan 22, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
| Merck Sharp & Dohme LLC May 12, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
| Astellas Pharma US Inc Dec 2, 2025 | Travel and Lodging Padcev · Oncology · travel to Phoenix, AZ | $598 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $448 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 3, 2025 | Consulting Fee Padcev · Oncology | $4,400 |
| Astellas Pharma US Inc Dec 2, 2025 | Travel and Lodging Padcev · Oncology · travel to Phoenix, AZ | $598 |
| Merck Sharp & Dohme LLC Dec 1, 2025 | Consulting Fee | $1,920 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee PADCEV · ONCOLOGY | $1,875 |
| Astellas Pharma US Inc Oct 10, 2025 | Consulting Fee Padcev · Oncology | $2,100 |
| Janssen Research & Development, LLC Aug 12, 2025 | Consulting Fee | $1,438 |
| Merck Sharp & Dohme LLC May 12, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $448 |
| Astellas Pharma Global Development Feb 19, 2025 | Consulting Fee Padcev · Oncology | $3,713 |
| Janssen Research & Development, LLC Jan 24, 2025 | Consulting Fee | $431 |
| Merck Sharp & Dohme LLC Jan 22, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $434,124 in research payments for these studies, mostly to the institutions running them.
- A Phase 1,2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma MIUC INTerpath-005
Merck Sharp & Dohme LLC - A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Inelig…
Merck Sharp & Dohme LLC - A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company · Recruiting · NCT06465069 - A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1,L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma KEYMAKER…
Merck Sharp & Dohme LLC - A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma KEYMAKE…
Merck Sharp & Dohme LLC - A phase 2 multicohort openlabel multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48ADC alone or in combination with pembrolizumab in subjects with locallyadvanced unresectable or me…
Seagen Inc. - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - Study name not reported
Organon Llc - A phase 2 multi cohort open label multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48 adc in subjects with HER2 expressing locally advanced unresectable or metastatic urothelial car…
Seagen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.